Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more

Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE phase 3 readout, the rational for myostatin inhibition in obesity, and recent ASCO data.